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The mammalian immune system is
characterized by a magnificent
division of labor between lymphocyte
subsets that act in concert to sense
and fight the widest possible range of
threats to health and life. Broadly
speaking, classical CD4+ T cells screen
extracellular spaces for the presence
of foreign structures that have been
captured, processed and bound to
major histocompatibility complex
(MHC) class II by antigen-presenting
cells. CD8+ T cells are in turn wired
to inspect host tissues for the
expression of abnormal proteins
displayed in the context of MHC class
I during viral infection or
malignancy. Natural killer cells
complement these responses by
surveying the body for loss of
functional MHC molecules on
infected or transformed host cells.
cd T cells pride themselves in
having so far escaped the scientists’
desire to assign them a clear role
within conventional schemes of
immunology, not least because of their
apparent lack of a general restricting
element akin to MHC. Rather,
evidence is mounting that in many
cases these “unconventional” T cells
may instead detect metabolic changes
in host cells and survey tissue integrity
by monitoring expression of stress-
related self-antigens and nonpeptide
molecules in the absence of orthodox
antigen presentation.1,2 Two elegant
studies by Rigau et al.3 and
Karunakaran et al.4 now make an
important contribution toward our
understanding of how a subset of
human cd T cells responds to such
nonpeptide compounds.
In the vertiginous field of
unconventional T-cell biology, human
Vc9/Vd2 T cells are strangers in a
strange land. Vc9/Vd2 T cells typically
comprise 0.5%–5% of circulating
blood T cells and respond readily to
both self- and non-self-metabolites,
often referred to as “phospho-
antigens.”2 By far the most potent of
these is (E)-4-hydroxy-3-methyl-but-
2-enyl pyrophosphate (HMB-PP), a
microbial precursor of isopentenyl
pyrophosphate (IPP), the ubiquitous
building block of all higher
isoprenoids. HMB-PP is produced by
the majority of Gram-negative bacteria
and bad microbes including
Mycobacterium tuberculosis,
Clostridium difficile and Listeria
monocytogenes, as well as by malaria
parasites and Toxoplasma gondii.
Humans do not produce HMB-
PP, instead generating IPP via the
mevalonate pathway, one of the
commercially most attractive drug
targets in the body. Inhibition of b-
hydroxy b-methylglutaryl-coenzyme
A reductase by statins abrogates
downstream generation of IPP, and
consequently, the synthesis of higher
isoprenoids, thereby lowering
cholesterol levels in individuals at
risk of cardiovascular disease.
Further along in the mevalonate
pathway, inhibition of farnesyl
pyrophosphate synthetase can be
achieved with aminobisphosphonate
drugs such as zoledronate, which is
used in the clinic to halt excessive
bone resorption in individuals with
osteoporosis, multiple myeloma and
bone metastasis, but also leads to
the elevation of levels of upstream
metabolites, including IPP, within
zoledronate-treated cells. These
zoledronate-induced metabolic
troubles of a mevalonate pathway
out of control are sensed by Vc9/
Vd2 T cells and can be counteracted
using statins.
The mysterious ways underlying
the Vc9/Vd2 T-cell responsiveness to
HMB-PP, IPP and zoledronate have
long puzzled scientists.5 Ground-
breaking research by Rigau et al.3 and
Karunakaran et al.4 now sheds neon
lights on this phenomenon,
identifying the key role of
butyrophilin 2A1 (BTN2A1) in Vc9/
Vd2 T-cell phosphoantigen sensing
(Figure 1). BTN2A1 is joining an
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illustrious family of only a handful of
confirmed ligands for human cd T
cells that comprise diverse molecules
such as endothelial protein C
receptor, annexin A2 and, most
recently, also the MHC-related
molecule MR1.2,6
The clear implication of BTN2A1
in human Vc9/Vd2 T-cell responses
is a sort of homecoming for cd T-cell
aficionados, because the related
protein BTN3A1 had already been
shown to be required for Vc9/Vd2 T-
cell responses to phosphoantigens.7
Other butyrophilin family members
with cd T-cell regulatory activity
include BTNL3/BTNL8 (human
Vc4+ T cells), Btnl1/Btnl6 (mouse
Vc7+ T cells) and Skint1/Skint2
(mouse Vc5+ T cells).8 Of note,
HMB-PP and IPP were previously
shown to bind to the intracellular
B30.2 domain of BTN3A1,9 yet it
has remained unclear whether and
how this binding might translate to
recognition of the extracellular
portion of BTN3A1 via the Vc9/
Vd2 T-cell receptor (TCR).
Additional factors have been
postulated to be involved in this
response, including F1-ATPase,
periplakin, RhoB and ABCA1, yet
none of these acts as direct ligand
for the Vc9/Vd2 TCR.2
First and foremost, the papers by
Rigau et al.3 and Karunakaran et al.4
are a striking testimony to the power
of modern techniques that have
allowed scientists to propel forward
Figure 1. Vc9/Vd2 T-cell response to microbial antigens and self-phosphoantigens—the little things that give it away. BTN2A1 binds directly to
the Vc9 chain of the cd TCR, possibly as homodimer, while also interacting closely with BTN3A1, which may additionally form homodimers and/
or associate with BTN3A2 or BTN3A3. Whether these contacts occur simultaneously, or involve sequential interactions at another time, another
place remains to be resolved as indicated by the question marks in the figure. In particular, the role of BTN2A2 is unclear at present.
Phosphoantigens may reach the B30.2 domain of BTN3A1 via various pathways: intracellularly upon changes in the metabolic flux through the
mevalonate pathway, for example, after zoledronate treatment, or upon release from pathogens in the cytosol or in phagocytic vesicles.
Exogenous HMB-PP and IPP may be shuttled directly into the cytosol, or be taken up by pinocytosis or endocytosis. Phosphoantigen binding to
BTN3A1 may take place in the cell surface membrane or, far away so close, in a putative loading compartment inside the cell, and may be aided
by other BTN3 isoforms and cofactors. Of note, baseline responses to BTN2A1 in the absence of phosphoantigens are still detectable, and the
precise ligand specificity of the CDR3 regions of the Vc9/Vd2 TCR remains unknown. BTN2A1, butyrophilin 2A1; HMB-PP, (E)-4-hydroxy-3-methyl-
but-2-enyl pyrophosphate; Ig, immunoglobulin; IPP, isopentenyl pyrophosphate; TCR, T-cell receptor.
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like a bullet the blue sky concepts
that could not easily be tested with
older methodologies. Rigau et al.
employed a genome-wide CRISPR/
Cas9 (clustered regularly interspaced
short palindromic repeats/CRISPR-
associated protein 9) knockout
screen of LM-MEL-62 melanoma
cells that stained brightly with a
soluble Vc9/Vd2 TCR tetramer, and
identified BTN2A1 as the most
significant guide RNA responsible
for tetramer reactivity.3 In support,
knockdown and re-expression
experiments together with the use of
anti-BTN2A1 monoclonal antibodies
confirmed a crucial role of BTN2A1
in mediating binding of the Vc9/Vd2
TCR tetramer, and in driving
responses to HMB-PP and
zoledronate. Karunakaran et al.
utilized an unbiased screen of
radiation hybrids between BTN3A1-
transduced rodent cells and CHO cells
carrying human chromosome 6.10
RNAseq analysis of positive clones
mediating phosphoantigen-dependent
activation of Vc9/Vd2 TCR
transfectants identified a 580-kb island
containing BTN3A1, BTN3A2,
BTN3A3, BTN2A1 and BTN2A2 as
candidates. Specific knockdown of
BTN2A1 but not BTN2A2 numbed
Vc9/Vd2 TCR responses to HMB-PP
and zoledronate, whereas re-
expression of BTN2A1 restored
binding of soluble Vc9/Vd2 TCR
tetramers to BTN2/ cells, thereby
corroborating and extending the
findings of Rigau and colleagues.
Of note, both groups report that
BTN2A1 binds within seconds to
Vc9/Vd2 as well as Vc9/Vd1 TCRs,
and provide evidence for a direct
interaction between BTN2A1 and the
Vc9 chain while ruling out contacts
with the Vd2 chain. Carefully
targeted mutation of the Vc9 chain
combined with structural modeling
mapped a series of key amino acids
involved in this interaction, in
particular R20, E70 and H85.3 Vice
versa, targeted mutation of R65,
R124, Y126 and E135 in the BTN2A1
protein completely abrogated binding
to the Vc9/Vd2 TCR.4
So how does the discovery of
BTN2A1 as a Vc9/Vd2 ligand square
with the previous implication of
BTN3A1 in phosphoantigen sensing?
Well, sometimes you can’t make it on
your own. Both molecules appear to
be essential but not sufficient on their
own, and only coexpression of
BTN2A1 and BTN3A1 elicits Vc9/Vd2
T-cell responses to HMB-PP or
zoledronate. And despite both
molecules possessing intracellular
B30.2 domains, phosphoantigens
appear to only bind to the B30.2
domain of BTN3A1 but not to that of
BTN2A1.3 Using confocal microscopy
and F€orster resonance energy transfer
analyses, Rigau et al. in fact
demonstrate that BTN2A1 and
BTN3A1 colocalize at the cell surface
and that the two molecules associate
intracellularly and extracellularly.3
These results are complemented by
crosslinking and immunoprecipitation
studies by Karunakaran et al. using a
16-A spacer, indicating a close and
possibly direct association of BTN2A1
with BTN3A1 on the cell surface.4
The model emerging from these
findings suggests that BTN2A1
exclusively touches the germline-
encoded HV4 region of the Vc9
chain, with no involvement of the
Vd2 chain, whereas phosphoantigen
specificity of the TCR is conferred
by BTN3A1 recognition via both the
CDR3 region of the Vc9 chain and
the CDR2 region of the Vd2
chain.3,4 But is that all? The
potential contribution of the other
members of the BTN2/3 family, and
whether target recognition occurs
with or without them, remains
elusive. Previous reports suggested
that BTN3A2 and/or BTN3A3 may
help facilitate surface expression of
BTN3A1 and form heterodimers.
Here, BTN3A2 was not required
for the phosphoantigen-dependent
activation of Vc9/Vd2 T cells by
BTN2A1–BTN3A1 co-transfected
hamster cells, but nevertheless
enhanced the response moderately.3
In addition, BTN2A2 appears to be
capable of binding to the Vc9 chain
with similar affinity to BTN2A1,
with as yet unknown relevance.4 To
walk on, we will require further
biochemical and structural work
into the precise contribution of the
different BTN2 and BTN3 isoforms,
the role of the B30.2 domains and
their discrimination between self-
and non-self phosphoantigens, the
vesicular trafficking pathways that
shuttle phosphoantigens to the
cytosol, and characterization of the
intracellular and extracellular partner
molecules involved (Figure 1).
The implications of these new
findings are manifold and light the
way for future investigations. For
instance, it is tempting to speculate
that BTN2A1 and/or BTN3A1 may
play a role in the exit of positively
selected mature Vc9/Vd2 T cells
from the thymus. Moreover, given
that BTN2A1–BTN3A1 complexes
can be formed independently of
phosphoantigens and that BTN2A1
elicits a relatively small but
discernible baseline response on its
own,5 there is a light for the
existence of a further, true antigen
that is recognized by the Vc9/Vd2
TCR in a CDR3-mediated fashion
but has remained invisible so far.
Intriguingly, such a hypothetical
ligand/cofactor must be conserved
evolutionarily — BTN2A1–BTN3A1-
transduced mouse and hamster cells
are targeted readily by human Vc9/
Vd2 TCRs,3,4 and for the first time a
nonprimate original of the species,
the alpaca (Vicugna pacos), has been
reported to also possess a
phosphoantigen-reactive Vc9/Vd2
T-cell subset.11 Finally, given the
strong translational and applied
interest in Vc9/Vd2 T cells, BTN2A1
is a highly relevant target candidate
for the development of agonistic
and/or antagonistic miracle drugs
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in the context of microbial
infection, autoimmunity and tumor
immunotherapy.
The seminal publications by Rigau
et al. and Karunakaran et al. on
BTN2A1 as a novel ligand for human
Vc9/Vd2 T cells extend previous
reports of similar c-chain-specific,
superantigen-like interactions of
other butyrophilin family members
with cd T cells in humans and in
mice, evoking Susumu Tonegawa’s
unforgettable prediction that cd T
cells “may be involved in an entirely
new aspect of immunity,”12 clearly
distinct from classical CD4+ and
CD8+ T cells and MHC-restricted
adaptive immunity. Yet one caveat
remains. We may be one step closer
to knowing but with regard to
understanding the antigen specificity
of the cd TCR CDR3 region we
still haven’t found what we are
looking for.
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